Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC
Clinical trial NCT06424821 · UNKNOWN
Trial details
- NCT number
- NCT06424821
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-04
- Primary completion
- 2024-09-04
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.